L-Carnitine’s Role in Modulating COVID-19

The COVID-19 pandemic has highlighted the need for effective treatments and supplements.

A recent pilot study examined the potential of L-carnitine in modulating the effects of SARS-CoV-2 infection. This post summarizes the findings of this study.

Study Overview

The study, conducted by researchers in Brazil, was a double-blind, placebo-controlled trial involving 223 participants. It aimed to evaluate the safety and efficacy of L-carnitine L-tartrate in individuals at risk of SARS-CoV-2 infection or those with mild COVID-19 symptoms.

Key Findings

• Reduction in Inflammation: L-carnitine supplementation was associated with reduced inflammatory markers and improved lung lesions in COVID-19 patients.
• Improved Coagulation Profiles: The study found that L-carnitine helped modulate coagulation pathways, which is crucial in preventing complications in COVID-19 patients.
• Dosage: Participants received 2 grams of L-carnitine L-tartrate daily for 21 days.

Safety and Side Effects

The supplementation was well-tolerated, with common adverse events being mild, such as headaches and tiredness.

Conclusion

L-carnitine shows potential in reducing inflammation and improving lung health in COVID-19 patients. While further research is needed, these findings are promising. Access the full study here.